R. Rostagno

Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.

Rocco Piazza, Roberta Rostagno, Manuela Marega, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

Rocco Piazza, Roberta Rostagno, Leonardo Scapozza, 2003, The Lancet. Oncology.

Three novel patient‐derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors

S. Redaelli, C. Gambacorti-Passerini, R. Piazza, 2012, American journal of hematology.

Whole-Exome Sequencing Data – Identifying Somatic Mutations

A. Mogavero, C. Gambacorti-Passerini, R. Piazza, 2014 .

Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors.

J. Murray-Rust, L. Scapozza, A. Zambon, 2010, Bioorganic & medicinal chemistry.

Inhibition of RET tyrosine kinase by SU5416.

L. Scapozza, J. Bain, F. Formelli, 2006, Journal of molecular endocrinology.

Reply to P. Laneuville et al

S. Redaelli, C. Gambacorti-Passerini, R. Piazza, 2010 .

A New BCR-ABL1 Mutation (L248R) Is Highly Resistant to Imatinib, Bosutinib, Nilotinib and Dasatinib, but Can Be Inhibited by AP-24534 and DCC-2036

S. Redaelli, C. Gambacorti-Passerini, R. Piazza, 2010 .

A Bioinformatics Procedure to Identify and Annotate Somatic Mutations in Whole-Exome Sequencing Data

Roberta Spinelli, Rocco Piazza, Carlo Gambacorti Passerini, 2011, CIBB.